PGNY240517P22500
- 0.05
- 0.000.00%
Progyny Newsroom
Barclays Sticks to Its Buy Rating for Progyny (PGNY)
Progyny Is Maintained at Buy by Truist Securities
Progyny Is Maintained at Buy by Truist Securities
Express News | Progyny Inc : Truist Securities Cuts Target Price to $37.00 From $46.00
Truist Securities Cuts Price Target on Progyny to $37 From $46, Keeps Buy Rating
Progyny (PGNY) has an average rating of buy and price targets ranging from $30 to $48, according to analysts polled by Capital IQ. Price: 27.15, Change: -0.40, Percent Change: -1.45
Progyny Price Target Maintained With a $48.00/Share by Cantor Fitzgerald
Progyny Price Target Maintained With a $48.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $48 Price Target
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Arvinas Holding Company (ARVN) and Progyny (PGNY)
Express News | Progyny Inc : JP Morgan Cuts Target Price to $41 From $51
Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Progyny's executives will participate in a
Analysts' Top Healthcare Picks: Xenon (XENE), Progyny (PGNY)
Progyny Is Maintained at Overweight by Barclays
Progyny Is Maintained at Overweight by Barclays
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays
Express News | Barclays Maintains Overweight on Progyny, Lowers Price Target to $30
Progyny (NASDAQ:PGNY) Has More To Do To Multiply In Value Going Forward
Express News | Progyny : Barclays Cuts Target Price to $30 From $48
Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)
Progyny, Inc. (NASDAQ:PGNY) Q1 2024 Earnings Call Transcript
Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'
On Thursday, Progyny Inc (NASDAQ:PGNY) reported first-quarter sales of $278.1 million, up 7.6% year over year, missing the consensus of $289.46 million, primarily due to the increased number of client
Progyny Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 37.85% Canaccord Genuity $46 → $37 Maintains Buy 05/10/2024 52.76% BTIG $50 → $41 Maintains Buy
Top Midday Decliners
MacroGenics (MGNX) plummeted past 75% amid heavy trading after the company said five patients died in an ongoing mid-stage study of its experimental drug to treat a type of prostate cancer. BMO downgr